Current research endorses the use of GLP-1 RAs in the cardiometabolic management of patients with T2DM, obesity, and high cardiovascular risk, since these agents, in addition to metabolic control, address some of the important pathophysiological drivers of cardiovascular disease. The gene discussed is GCG; the disease is Obesity.